Biological characteristics of a new human glioma cell line transformed into A2B5 stem cells by unknown
Li et al. Molecular Cancer  (2015) 14:75 
DOI 10.1186/s12943-015-0343-zRESEARCH Open AccessBiological characteristics of a new human glioma
cell line transformed into A2B5+ stem cells
Yanyan Li1†, Hangzhou Wang1†, Ting Sun1, Jinming Chen1, Lingchuan Guo2, Haitao Shen1, Ziwei Du1
and Youxin Zhou1*Abstract
Objective: The new glioma cell line SHG-139 was established and its phenotype, tumorigenicity, pathological
characteristics, derived stem cells SHG139S were studied.
Methods: Immunohistochemistry was used to assess expressions in the patient and mouse tumor tissues, SHG-139
and SHG-139S. Primary SHG-139 culture was performed, cell proliferation, cell cycle and genetic characteristics were
assessed. MiRNA (Micro RNA) and LncRNA (Long non-coding RNA) microarray was performed.
Results: We found that the glioma tissue was positive for A2B5 (Glial precursors ganglioside), GFAP (Glial fibrillary
acidic protein), S-100 (Acid calcium bingding protein), VEGF (Vascular endothelial growth factor), VEGFR (Vascular
endothelial growth factor receptor) and negative for Ki-67 (Nuclcar- associated antigen). SHG-139 proliferated
significantly within 24h; its total number of chromosomes was 68; ratios of SHG-139 and SHG-139S cells in G1
phase were highest. SHG-139 cells were positive for A2B5, GalC (Galactocerebrosides), GFAP, S-100 and Vimentin,
while SHG-139S cells were positive for A2B5, Nestin, and NG2 (Neuron-glia antigen2), and negative for Vimentin
and IDHR132H (Isocitrate dehydrogenase); cells rarely stained for CD133 (Cluster of differentiation133). SHG-139
intracranial xenografts expressed GFAP, but no overt oligodendroglioma was observed. In SHG-139S xenografts,
GFAP and S-100 were expressed, while CD133 was not detected; a few A2B5+ cells were found at tumor edges,
and typical oligodendroglioma were obtained. In addition, SHG-139S xenograft tumors were more aggressive
than those of SHG-139. Anti-mouse CD31 (Cluster of differentiation31) staining revealed murine vessels at the
border between xenograft tumor and normal brain tissue; Anti-human CD34 (Cluster of differentiation34) staining
was negative. Biochip technology of SHG139S showed several miRNA and lncRNA were differently expressed in
SHG139 and SHG139S.
Conclusions: SHG-139 was an astroglioma cell line which yielded stem cells SHG-139S. SHG-139S cells constituted an
A2B5+/CD133− GSC subgroup.
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Glioma is the most common intracranial malignancy in
adults, and is associated with poor outcomes. Emerging
evidence suggests there is a rare population of tumor cells,
called glioma stem cells (GSCs), which are responsible for
glioma initiation, propagation, resistance to radiotherapy
and recurrence of disease [1]. We previously established* Correspondence: zhouyouxin@suda.edu.cn
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unless otherwise stated.the first human glioma cell line SHG-44 in china [2],
which has positively impacted glioma research in our
country. To further characterize glioma, this study estab-
lished a glioma cell line, which can transform into glioma
stem like cells with A2B5+. This cell line were obtained
from surgical resection of brain tumor tissue of a 23-year-
old male patient (database specimen No. 139, SHG-139),
so this cell line was named SHG139. The patient’s clinical
diagnosis was WHO II grade fibrous astrocytoma. Al-
though there are many cell lines from GBM (Glioblastoma
multiforme), permanent lines from low grade glioma haveis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gap in low grade glioma biological and clinical studies.
Molecular biological characteristics of the cell line, patho-
logical and histological characteristics of intracranial and
subcutaneous tumor patterns related this cell line will be
detailed in this work.Results
Primary culture of SHG-139 cells and their molecular
characteristics
Primary cells from fresh tumor tissues were cultured,
and glioma cells grew slowly within five generations.
They began to grow significantly faster at the seventh
generation, and intended to be stable, cell morphology
also changed. Cells were clear and mostly bipolar; somas
were mostly fusiform. Single cell clone assay was carried
in the 20th generation of SHG-139 cells, they were ad-
herent, with irregular cell morphology; nuclear atypia
was significant, with visible round and irregular polyg-
onal shape; cells were not clear; pseudopodia were
formed in few tumor cells, while protrusion was clearly
formed in most tumor cells (Figure 1, A). Immunofluor-
escence staining was performed with 20th generation
cells, and the expression of DH1R132H, A2B5, GalC,
Vimentin, astrocyte marker GFAP and S-100 were posi-
tive (Figure 2, A1-A6).
SHG-139 cells were passaged to the 60th generation,
and tumor cells were adherent, and showed irregular nu-
clei clearly demarcated and significant cell protrusions,
was similar to SHG-139 in the 20th generation. Immuno-
fluorescence staining of glioma cells (60th generation),
assessed by laser confocal microscopy, revealed the pres-
ence of IDH1R132H, A2B5, GalC, Vimentin, GFAP, and
S-100 (Figure 2, B1-B6).Figure 1 Human glioma stem cell spheres SHG-139S derived from SH
microscope (×400); B, C: SHG-139S, derived from SHG-139 at the 1st and 10
without EGF, bFGF and fetal bovine serum, SHG-139s cells were adherent,Molecular characteristics of SHG-139S and its differentiated
cells cultured in DMEM/F12 with fetal bovine serum
Glioma stem like cell spheres of the 10th generation
were assessed by immunofluorescence, 4.2 ± 1.29% SHG-
139S cells in spheres were CD133+ (Figure 2, C1) and
84.12 ± 9.96% cells stained positive for A2B5 (Figure 2,
C2). SHG-139S were confirmed as A2B5+ /CD133− GSC
(Glioma stem cells) subset. Next, the expression of differ-
ent glioma molecular markers in different GSC subsets of
SHG-139S were analyzed. In A2B5+ /CD133− SHG-139S
glioma stem like cell spheres, the percentages of positive
cells for IDH1R132H (Figure 2, C1), Nestin (Figure 2, C3),
NG2 (Figure 2, C4) and Vimentin (Figure 2, C5) were re-
spectively 36.77 ± 13.19%,73.86 ± 5.01%, 49.12 ± 12.83%
and 73.37 ± 2.09%.
Cells in the 20th generation were cultured in NSCM
(neural stem cell medium), and glioma stem like cell
spheres were formed after 1 week in suspension, but there
was still a large number of adherent cells (Figure 1, B).
When passaging, only suspended cell spheres were col-
lected and the adherent ones discarded. Until the 10th
generation, a large number of glioma stem like cell
spheres were observed in suspension, with only few adher-
ent cells. These cells were named SHG-139S (Figure 1, C).
SHG139S was cultured in DMEM/F12 medium without
bFGF (basic fibroblast growth factor) and EGF (epidermal
growth factor) and containing 10% fetal bovine serum,
cells were adherent after 6h, with more adherent cells
among spheres; almost all cells were adherent after two
days (Figure 1, D-F).
Cell proliferation and chromosome karyotype of SHG-139
cells
Cell proliferation of SHG-139 cells was assessed by
MTT assay, 570nm OD value increased obviously withinG-139 after culture in NSCM. A: SHG-139 at the 20th generation, light
th generations, light microscopy (×200); D-F: In DMEM/F12 medium
cell morphology changes at 6 h, 24 h, 48 h, light microscope (×200).
Figure 2 Molecular markers expression of SHG-139, SHG139S A1-A6:. Related markers expression of SHG139 in the 20th generation:
IDH1R132H (+), A2B5 (+ + +), GalC (+ +), Vimentin (+ + +), GFAP (+ + +) and S-100 (+ +), B1-B6: Related markers expression of SHG139 in the
60th generation: IDH1R132H (+), A2B5 (+ + +), GalC (+ +), Vimentin (+ + +), GFAP (+ + +) and S-100 (+ +), C1-C6: Related markers expression of
SHG139S in the 10th generation: IDH1R132H (+ +), A2B5 (+ + +), Nestin (+ + +), NG2 (+ + +), Vimentin (+ +) and CD133 (-), DAPI is a nuclear dye
used as counterstain in immunofluorescence (×400).
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showed that SHG-139 cells grew significantly within
48h, then cells grew slowly (Figure 3).
SHG-139 cells of the 20th generation were used for G-
banding karyotype analysis after digestion, fixation, andstaining. Samples were analyzed under a microscope.
The total number of chromosomes was 68; their shape
was irregular distortion (Figure 4, A). Chromosome
karyotype pairing showed that chromosome 16 was de-
leted; 7, 12, X and Y were one copy; 1, 2, 4, 5, 8, 10, 11,
Figure 3 Cell proliferation of glioma cell SHG139. Horizontal axis
is time, vertical axis is absorbance value.
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copies; 18 was four copies; 20 was five copies; 3,13, and
19 were six copies and 14 was eight copies (Figure 4, B).
Clinical radiological and pathological data of the patient
Pre-surgery MRI indicated lesions on the rear left frontal
lobe, with uniform long T1, T2 signals, which were not
increased significantly after enhancement (Figure 5, A1-
A2). Histological examination after surgery showed overt
nuclear atypia; no obvious mitotic count, necrosis and
microvascular endothelial proliferation; medium tumor
cell density; mostly “naked nucleus-like”; irregular nu-
clear hyper-chromia; loose fiber matrixes, which were
formed in tumor cell protrusions; clear and visible micro-
capsules; WHO II grade fibrous astrocytoma (Figure 5,
A3). Immunohistochemistry revealed the expression of
A2B5, GFAP, S-100, VEGF and VEGFR was tan or brown
dots, mainly located in the cell cytoplasm and membrane.Figure 4 Chromosome karyotye of glioma cell SHG139. A-B:. OriginalSome S-100+, VEGF+, VEGFR+ nuclei were also brown. A
little expression of Ki-67 was observed (Figure 5, A4-A9).
Pathological analysis and immunohistochemistry of
SHG-139 and SHG-139S subcutaneous xenografts
Subcutaneous xenografts of SHG-139 and SHG-139S
were compared. subcutaneous model of SHG-139 had
obvious boundary, tumor cells had a high density, with
spindle-, circular- and other irregular shape and dis-
played overt nuclear atypia ((Figure 5, B1-B2). Immuno-
histochemistry of tumor was positive for GFAP and
A2B5, however, obvious oligodendroglioma components
were not found in this tumor model (Figure 5, B3-B4).
Intracranial SHG-139S xenografts showed invasive
growth, with no obvious boundary (Figure 5, C1); tumor
cells also had a high density, with spindle-, circular- and
other irregular shape. Cells displayed overt nuclear atypia,
with rare megakaryocytes observed and pronounced nu-
clear mitosis, and low degree of differentiation (Figure 5,
C2). Microvascular hyperplasia was visible in some areas,
with no significant vascular thrombosis and false fence ne-
crosis changes. Oligodendroglioma ingredients featured
with typical “honeycomb” and “fried egg-like” structures
were identified (Figure 5, C3).
Immunohistochemical staining revealed low ratio of
A2B5+ tumor cells, suggesting that the majority of SHG-
139S glioma stem like cells expressing A2B5+ differenti-
ated in vivo (Figure 5, D1). Meanwhile, A2B5+ cells were
found at the edge, in a cord-like distribution, with no
obvious continuity with xenograft tumor cells, indicating
their aggressiveness (Figure 5, D2). A little expression of
CD133 was detected in xenograft tumor (Figure 5, D3),
GFAP and S-100 were detected (Figure 5, D4, D6). Inter-
estingly, GFAP and S-100 expression was detected in
oligodendroglioma ingredients of the tumor (Figure 5, D5,
D7). CD31 staining showed that murine tumor bloodand arrayed figure of karyotype of SHG139 cells.
Figure 5 MRI, H & E staining and immunohistochemistry data of the patient and mouse’s brain tissue. A1, A2: Pre-surgery contrast-
enhanced MRI images of T1WI and T2WI sequences of the patient; A3: Patient’s pathology H & E staining, light microscopy (×400); A4-A9:
Glioma tissue immunohistochemistry: A2B5 (+ + +), GFAP (+ +), VEGFR (+ +), S-100 (+ +), VEGF (+ + +), and Ki-67 (+) (×400); B1-B2: H & E
staing of intracranial xenograft of SHG-139, light microscope (×100, ×400); B3-B4: GFAP and A2B5 staining of intracranial xenograft of SHG-139, light
microscope (×1000); C1-C3: HE of intracranial xenograft of SHG-139S, C1: Low magnification microscopy showed invasive growth of tumor cells
(×100), C2: High magnification microscopy showed local area in the xenograft (×400), C3: “Fried egg-like” cells-based high cell density areas were
visible in another area of the xenograft (×400); D1-D9: Immunohistochemistry of intracranial xenograft of SHG-139S: D1-D2: Expression of intratumor
and peritumoral A2B5 (+) (×400); D3: Expression of CD133 in the xenograft (+) (×400); D4, D6: Expression of GFAP (+ +) and S-100 (+ +) in the xenograft
(×400); D5, D7: Expression of GFAP (+ + +) and S-100 (+ + +) intratumor oligodendroglioma components in the xenograft (×400); D8, D9:0020cxxCD31
(+) and CD34 (+) staining (×400).
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and normal brain tissue (Figure 5, D8). Indeed, xenograft
tumor cells invaded outward along murine blood vessels;
immunohistochemical staining with anti-human CD34
antibody yielded no signals (Figure 5, D9).
Variant miRNA and lncRNA heatmap between SHG139
and SHG139S
Total RNA extracted from SHG139 and SHG139S were
treated with different methods, miRNA and lncRNA
microarray analysis were performed according to rele-
vant assays. Fortunately, we obtained variant expression
of miRNA and lncRNA between SHG139 and SHG139S
(Figure 6).
Discussion
Cell culture is one of the most powerful tools in cancer
research, with 60 years of history so far [3]. The earliestglioma cell lines cultured were rat glioma C6 and 9L,
and human glioma U251 and U87 [4-6]. Professor Ziwei
Du generated the first glioma cell line SHG-44 in our la-
boratory in 1984. The glioma cell line SHG-139 studied
herein was gained successfully in serum-containing
RPMI 1640 from WHO II grade astrocytoma (fiber type),
and can be stably passaged. SHG139 in the 20th and 60th
generations had the same molecular markers and cell
morphology: GFAP, S-100 and Vimentin were expressed,
and tumor cells were diploid or polyploid. Immunohisto-
chemistry of tumor specimens showed the expression of
A2B5, GFAP, S-100, VEGF and VEGFR, while Ki-67 was
not detected.
Recent studies have shown that brain cancer evolves
from a specific tumorigenic cell subset with highly self-
renewal potential called tumor or cancer stem cells [7].
There are many culture methods for glioma stem cells:
flow cytometry for molecular markers and immuno-
Figure 6 Heatmap of variant miRNA and lncRNA in SHG139 and SHG139S.
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include separation of side population (SP) cells and
auto-Fluorescence [8-11]. Under NSCM with bFGF and
EGF, N2 and without serum, GSCs were obtained from
human glioma primary cultures or glioma cell lines,
maintained parental tumor molecular phenotype, and
even kept parental genotype [12-14]. This method is also
known as sphere forming method; GSCs grow in the
culture as suspension since they are neural stem cells
(NSC) [15,16]. The new glioma cell line showed stable
passage characteristics, and experimental reproducibility
was good. GSCs have been gained from cell lines under
NSCM in a number of studies, and the use of these
GSCs has contributed significantly to reveal therapeutic
targets for glioma [17-20].
In this study, SHG-139S glioma stem cell spheres were
acquired from SHG-139 glioma cells under NSCM, and
sphere formation rate was high. Many studies have
shown that sphere formation rate of glioma stem cells is
closely related with patient prognosis [21,22]. Interest-
ingly, decreased numbers of G1 phase cells were ob-
served in SHG-139S, while the rate of G2 phase cells
was increased, compared with the values obtained for
SHG-139 cells; these differences were likely related to
the effects of bFGF and EGF on tumor cells. Indeed,EGF and bFGF were shown to play important roles in
the development of NSC and nervous system, and self-
renewal of GSCs was also closely related to EGF and
bFGF [23-25].
Immunofluorescence indicated no expression of
CD133, while A2B5 was detected in SHG-139s. CD133
is a well-known GSC surface marker; however, glioma
stem cells with CD133− have been identified [26]. Second-
ary sphere formation assay confirmed that SHG-139S have
self-renewal capacity; immunofluorescence confirmed the
expression of Vimentin in cells with the neural stem cell
marker Nestin+; when SHG-139S were induced to differ-
entiate in NSCM containing serum and without bFGF and
EGF, adherent cells were observed, and GFAP, the early
neuronal marker β-III Tubulin and the oligodendroglioma
marker GalC were expressed. A2B5 was also previously
confirmed as glioma stem cell marker [27,28].
With the development of GSC culture technology,
GSCs with parent tumor genetics, genotype characteris-
tics and heterogeneity characteristics in NSCM without
serum, its xenograft has an advantage in affinity [29].
SHG-139S cells with A2B5 +/CD133−were obtained in
NSCM and its pathological model was established. As
shown above, SHG-139 orthotopic xenograft were low
invasive, but SHG-139S orthotopic xenograft model in
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distinct tumor histological types in SHG139S xenograft
were visible: one type was composed of irregularly shaped
cells, and was similar to glial cell sarcomatoid changes; the
other type showed oligodendroglioma changes and was
composed of relative regular “fried egg-like” shape cells.
Immunohistochemical staining of GFAP and S-100 was
positive in both pathological types. The specific pathology
may be associated with characteristics of GSCs (A2B5
+/CD133−).
A2B5 are markers of oligodendroglioma-II astrocytes
progenitors (O-2A progenitors). From the perspective of
differentiation lineage, O-2A progenitor cells differenti-
ate into oligodendroglioma or type II astrocytes cells,
but it has been shown that these cells cannot differenti-
ate into the latter, and are therefore mostly named as
oligodendrocyte precursor cells (OPCs) [30]. It was pro-
posed that oligodendroglioma tumor is formed by GSCs
with A2B5 phenotype, which determines their further
differentiation outcome. Meanwhile, immunohistochem-
istry of A2B5 in SHG-139S xenografts suggested that
GSCs with A2B5+ differentiated in vivo and mostly lost
the A2B5 molecular phenotype. Indeed, tumor cells with
A2B5+ were arranged in cord-like distribution at the
outer edge of the tumor, indicating their aggressiveness.
In this xenograft model, anti-human CD34+ tumor cells
were not found; anti-mouse CD31 staining showed mur-
ine tumor blood vessels at the edge of the xenograft,
rarely in the center; anti-mouse CD34 staining revealed
that murine tumor blood vessels outside the xenograft
were surrounded by a high density of tumor cells, sug-
gesting that SHG-139S cells invade outside along mur-
ine vascular system. Although SHG-139S cells with
A2B5+/CD133−appeared with morphological changes
similar to vascular mimicry in DMEM/F12 medium
without EGF, bFGF and containing fetal bovine serum,
this was not observed in vivo, suggesting that these
GSCs were not closely related to formation of vascular
mimicry.
Gene microarray was used to study SHG-139S and its
parent cell line SHG-139, and some miRNAs and lncRNAs
were different in two cells. Further experiments are under-
way in our group to unveil the effects of the different miR-
NAs and LncRNAs identified on glioma.
In conclusion, much attention should be paid on hetero-
geneity of glioma in order to solve current problems of
chemotherapy and further targeted therapy. Comprehen-
sive understanding of glioma cell pathology is one of the
most promising ways to overcome the disease. Improve-
ments of glioma cell culture technology, optimization of
glioma model, progress of biochemical research tools,
intelligence of bioinformatics, and multi-level comprehen-
sive research tool will bring new breakthrough for basic
research and clinical treatment of cancers.Materials and methods
Clinical sampling and experimental animals
Glioma tissue sample was obtained from a patient at the
department of neurosurgery in the First Affiliated Hos-
pital of Soochow University in 2010. This study was ap-
proved by the ethics committee of Soochow University.
The tissue in glioma sample library of our laboratory
was registered as Suzhou human glioma NO: 139, so
was named SHG–139. Nerve tumors’ standard of WHO
in 2007 was used for diagnosis and tumor was taken out
in sterile condition and packed into a sterile culture bottle
and formaldehyde solution; a portion of the sample was
frozen in liquid nitrogen. Twenty BALB/C nude mice
were purchased from the institute of model animals of
Nanjing University and housed in SPF nude mouse room
of our laboratory.Primary cell culture and subculture of human glioma
Fresh glioma sample was washed and minced in PBS
(1×) followed by 0.25% enzymatic dissociation at 37°C
for 20 min. The isolated cells were resuspended in RPMI
1640 supplemented with 2 mM L-glutamine, 1% Penici-
lin–Streptomycin and 10% Fetal Bovine Serum (GIBCO,
Invitrogen Corporation, USA). Next, cells were seeded
in 25 cm2 culture flasks and maintained in a humidified
incubator (Thermo Fisher Scientific Inc.3110, Waltham,
MA, USA) with 5% CO2 at 37°C, with the culture
medium replaced every other day. When cells reached
80% confluency, they were passaged after 0.25% trypsin
digestion. Single cell clone was performed at the tenth
generation and a stable passage cell line SHG139 was
gained and authenticated successfully (Additional file 1:
Table S1 and Additional file 2: Figure S1).Immunofluorescence assay of SHG-139 and SHG-139S
Microslides were treated with poly-L-lysine, sterile
rinsed with water, UV sterilized, and dried. Single cell
suspensions or sphere cell suspensions were dropped on
glass slides. After fixation at room temperature with 4%
paraformaldehyde, cells were blocked with goat serum
and permeabilized with 0.1% Triton X-100. Primary anti-
bodies A2B5 (mouse anti-human IgM), GC (rabbit anti-
human IgG), Vimentin (mouse anti-human IgM), GFAP
(mouse anti-human IgM) and S-100 (mouse anti-human
IgG) were added and incubated overnight at 4°C. Cells
were rinsed with PBS, and fluorescence-labeled secon-
dary antibodies were added and incubated at room
temperature, protected from light for 1h. Then cells
were counterstained with DAPI for 1 min, rinsed with
PBS and sealed with mounting medium. The slides
were respectively analyzed by fluorescence microscopy
(Olympus, Japan), confocal microscopy (Leica, German)
and optical microscopy (Olympus, Japan).
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SHG139S and SHG139S was induced to adherent cells
SHG-139 cells of the 20th generation were seeded into
6-well plates at a density of 1000 cells/well in neural
stem medium composed of DMEM/F12 (Gibco, USA),
20 ng/mL EGF (Invitrogen, USA), 20 ng/mL bFGF (Invi-
trogen), 1% N2 (Gibco) and 1% Penicilin–Streptomycin.
Cells were cultured at 37°C with 5% CO2, and cell
growth was assessed under an inverted phase contrast
microscope. Glioma stem cell spheres grew as suspension,
and half of the culture medium was replaced for passa-
ging. Glioma stem cells grown in suspension spheres were
gently drawn when passaging, and cultured. Glioma cells
derived from SHG-139 were named SHG-139S. To induce
differentiation of SHG-139S spheres, they were cultured
in DMEM/F12 medium contained 10% fetal bovine
serum, without bFGF, EGF and other growth factors.
Determination of glioma cell proliferation
2 × 103 cells were seeded in 96-well plates and cultured
in medium with 10% fetal bovine serum. A total of 6
groups were set: 0h, 24h, 48h, 72h, 96h, and 120h, each
time point had three replicates. At each time point, cells
in a well were treated with MTT solution (5 mg/ml in
PBS) 20ul, and incubated for 4h, supernatant medium
was discarded, added with 150 ul DMSO (dimethylsulf-
oxide), vibrated for 10 min. Cells were measured at 570
nm wavelength.
Genetic analysis of glioma
SHG-139 cells of the 20th generation were cultured for
four days. After treatment with colchicine (25 μg/ml) for
6 h, preheated 0.075 mM Kcl was added for 30 min at
37°C. Then, fresh stationary liquid (methanol: glacial
acetic acid =3:1) was added and cells were centrifuged at
1200 rpm for 10 min. The pellets were fixed at room
temperature for 10 min (4 times), and 500 μl stationary
liquid was added to resuspend the cells. Afterward, cell
droplets were applied to clean microslides that had been
soaked in 4 to 6°C ice water. The samples were baked in
80°C constant temperature drying oven for 15 min. After
Giemsa staining, the microslides were assessed by op-
tical microscopy.
Pathological examination and immunohistochemistry of
the patient glioma tissue
The tissue was fixed in 10% formalin, dehydrated with
ethanol gradient, permeabilized with xylene and paraffin
embedded. Then, serial 5 μm thick sections were cut,
deparaffinized with xylene, hydrated with ethanol gradi-
ent and stained with hematoxylin and eosin (H & E)
(Sigma-Aldrich, USA). Meanwhile, immunohistochemi-
cal staining was performed for A2B5, GFAP, VEGFR, S-
100, VEGF, and Ki-67 detection. Endogenous peroxidaseinactivation was carried out with 3% H2O2, and antigen
retrieval was performed in a microwave. Afterward, pri-
mary antibodies were added to each slide at appropriate
dilutions, and the sections incubated with biotin-labeled
secondary antibodies for 10 min. The final signals were
developed using the 3,3’-diaminobenzidine substrate
(DAB) (RD, America), The sections were analyzed by op-
tical microscopy after counterstaining with hematoxylin.
Pathological analysis and immunohistochemistry of
mouse xenograft tumor model
Glioma cells and stem cells were counted, resuspended
to 1 × 105 cells/μL, implanted in the right side of the
brain caudate nucleus of BALB/c nude mice (n = 5). The
whole process was completed in our nude SPF level
room. Nude mice were anesthetized by intraperitoneal
injection of 1% sodium pentobarbital, positioned on a
stereotactic apparatus with prone position, and the head
fixed. After alcohol disinfection of the skin of the top
head, a 0.5-1.0 cm longitudinal incision was made on
the frontal, 3.5 mm from cerebral midline, 2 mm frontal
to coronal seam. Then the skull was carefully drilled
with a dental drill. Micro-injector with10 μL tumor cell
suspension was fixed on the stereotactic apparatus, and
inserted vertically into brain parenchyma. The depth of
the needle tip was adjusted to 3 mm from cerebral sur-
face, and the tumor cell suspension was injected auto-
matically for 5 min. We observed the status of nude
mice with tumor after injection, including neurological
deficits. Survival times were recorded and mice were
sacrificed when they developed cachexia. Upon sacrifice,
the whole brain tissue was removed and fixed in forma-
lin. Pathological analysis and immunohistochemistry of
A2B5, CD133 (mouse anti-human IgG), GFAP, S-100,
CD31 (rabbit anti-mouse IgG), CD34 (mouse anti-human
IgG) of mouse xenograft tumors were performed.
MiRNA and lncRNA microarray analysis
Total RNA was extracted using the TRIZOL Reagent
(Life technologies, Carlsbad, CA, US), and assessed for
amounts and integrity on an Agilent Bioanalyzer 2100.
RNA samples were further purified by RNeasy mini kit
(QIAGEN, GmBH, Germany) and RNase-Free DNase
Set (QIAGEN, GmBH, Germany).
MiRNA were labeled by the labeling section of miRNA
Complete Labeling and Hyb Kit (Agilent technologies,
Santa Clara, CA, US). Each slide was hybridized with
100 ng Cy3-labeled RNA using the hybridization section
of miRNA Complete Labeling and Hyb Kit (Agilent tech-
nologies, Santa Clara, CA, US) in hybridization Oven
(Agilent technologies, Santa Clara, CA, US) at 55°C, 20
rpm for 20 hours. After hybridization, slides were washed
in staining dishes (Thermo Shandon, Waltham, MA, US)
with the Gene Expression Wash Buffer Kit (Agilent
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slides were scanned by Agilent Microarray Scanner (Agi-
lent technologies, Santa Clara, CA, US) with default set-
tings, Scan resolution = 5μm, PMT 100%, 5%. Data were
extracted by feature Extraction software 10.7 (Agilent
technologies, Santa Clara, CA, US), and normalized by
Quantile algorithm, Gene Spring Software 11.0 (Agilent
technologies, Santa Clara, CA, US).
Total RNA was amplified and labeled with the Low Input
Quick Amp Labeling Kit, One-Color (Agilent technologies,
Santa Clara, CA, US). Labeled cRNA was purified by
RNeasy mini kit (QIAGEN, GmBH, Germany). Each Slide
was hybridized with 1.65 μg Cy3-labeled cRNA using the
Gene Expression Hybridization Kit (Agilent technologies,
Santa Clara, CA, US) in Hybridization Oven. After 17
hours hybridization, slides were washed in staining dishes
with the Gene Expression Wash Buffer Kit. Slides were
scanned on Agilent Microarray Scanner with default set-
tings: Dye channel, Green; Scan resolution = 3 μm, 20 bit.
Data extraction and normalization was carried out as de-
scribed for miRNAs.
Additional files
Additional file 1: Table S1. Comparison of SHG139-20th, SHG139-60th
and SHG139S by 9 short tandem repeat (STR) markers (DOC), 9 STR
markers are same among them.
Additional file 2: Figure S1. DNA Profile of SHG139 and SHG139S used
in this study (DOC), the locations of STR markers were same, but peaks of
each STR marker among them.
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